Orthocell gears up for the commercialisation of Remplir in the US with the appointment of two key US based executives
Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis
Radiopharm Theranostics: Quarterly Activities & Cash Report and 4C for the quarter ended 30 September 2024
ImmVirX: First patients dosed in Phase 1b combination study in colorectal, gastric and ovarian cancer
Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships – CSL
Radiopharm Theranostics announces novel data presentation of RAD 202 at 2024 European Association of Nuclear Medicine (EANM) Annual Meeting